AskBio Inc
Clinical trials sponsored by AskBio Inc, explained in plain language.
A gene therapy company, subsidiary of Bayer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Gene therapy injection aims to repair failing hearts Results expected Oct 2026 (estimated)
-
Can a single gene infusion rebuild failing hearts?
Disease control CompletedThis early-stage trial is testing a new gene therapy called AB-1002 in people with advanced heart failure (NYHA Class III). The therapy is given as a single infusion directly into the heart's blood vessels, aiming to deliver a gene that may help heart muscle pump more effectively…
Phase 1 • Sponsor: AskBio Inc • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Gene therapy hope for pompe patients in early safety trial
Disease control CompletedThis early-phase study tested a new gene therapy called ACTUS-101 in 7 adults with late-onset Pompe disease. The main goal was to check safety and side effects. Participants received a single intravenous dose, and researchers monitored their health over time.
Phase 1 • Sponsor: AskBio Inc • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New study maps disease progression in Parkinson's and MSA
Knowledge-focused CompletedThis study follows 150 people with early Parkinson's disease or Multiple System Atrophy (MSA) for up to 18 months. Researchers will measure changes in motor symptoms, quality of life, and biomarkers to better understand how these diseases progress. The goal is to gather informati…
Sponsor: AskBio Inc • Aim: Knowledge-focused
Last updated Jul 29, 2026 00:00 UTC